The role of intravenous iron in anemia management and transfusion avoidance. （開啟新視窗）

Auerbach M, Goodnough LT, Picard D, Maniatis A.

出處‎: Transfusion 2008;48(5):988-1000.

檢索‎: PubMed 18346021

DOI碼‎: 10.1111/j.1537-2995.2007.01633.x

https://www.ncbi.nlm.nih.gov/pubmed/18346021 （開啟新視窗）

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. （開啟新視窗）

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

出處‎: BJU Int 2011;108(10):1582-7.

檢索‎: PubMed 21443653

DOI碼‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 （開啟新視窗）

The preoperative use of erythropoietin stimulating proteins prior to radical prostatectomy is not associated with increased cardiovascular or thromboembolic morbidity or mortality. （開啟新視窗）

Lepor H, Lipkin M, Slova D.

出處‎: Urology 2010;75(6):1424-8.

檢索‎: PubMed 20513505

DOI碼‎: 10.1016/j.urology.2009.06.095

https://www.ncbi.nlm.nih.gov/pubmed/20513505 （開啟新視窗）

Comparison of two different doses of preoperative recombinant erythropoietin in men undergoing radical retropubic prostatectomy. （開啟新視窗）

Nieder AM, Rosenblum N, Lepor H.

出處‎: Urology 2001;57(4):737-41.

檢索‎: PubMed 11306393

https://www.ncbi.nlm.nih.gov/pubmed/11306393 （開啟新視窗）